I'm not sure its much more than people noticing that NEU is in such a sweet spot:
- potential orphan drug in more than one condition
- Phase 3 trial approved with agreed end-points
- ample cash on hand to get through to trial start-up (with LW still available if needed)
- no urgency to sign a deal (very important as someone above has mentioned)
- several significant players interested in licensing / partnering
I'm no expert in the general biotech space, but I'm not imagining there are too many prospects out there with this profile.
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$16.48 |
Change
-0.290(1.73%) |
Mkt cap ! $2.076B | |||
| Open | High | Low | Value | Volume |
| $16.58 | $16.74 | $16.40 | $9.107M | 549.9K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 864 | $16.43 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $16.50 | 1668 | 1 |
View Market Depth
| Last trade - 16.10pm 25/07/2025 (20 minute delay) ? |
| NEU (ASX) Chart |